The Committee recommends preventing the unfair practices identified in the McGann case. Such situations could be eliminated by Congress in three ways. First, the anti-discrimination provision in section 510 of the Employee Retirement Income Security Act (ERISA, see Chapter 7) could be amended to prohibit various types of employer behaviour. For example, legislation could prohibit: (1) modification of benefits or modification of benefits without specific notice; (2) the reduction of coverage for a single disease; 3) reduction of benefits after a claim for benefits has already been submitted, etc. At the very least, the Committee recommends the adoption of an amendment making these practices illegal. A fundamental principle underlying many genomics research projects is that data must be shared with third-party researchers for secondary analysis. While this principle may be ethically commendable in promoting the usefulness of data, it is also based on the assumption that all researchers have equal access to data and comparable opportunities and skills to analyze it. This assumption does not apply to all researchers, especially those in low-income countries. Particular attention to equality and equity may be required to protect the interests of these researchers. They are treating a 21-year-old patient who describes herself as clumsy and has fallen several times. She fell and sprained her right ankle. They are currently treating their deficiencies related to this sprained ankle. In his medical history, it is noted that his brother was diagnosed with Charcot-Marie-Tooth disease (CMT).
Information about CMT disorders can be found on the GeneClinics website. Charcot-Marie-Tooth disease is most often inherited as an autosomal dominant disorder that can lead to peripheral neuropathy and cause coordination problems, clumsiness and falls. A family history of the disease could put your patient at increased risk of contracting the disease. You wonder if you should inform the patient about genetic risks and testing. In the context of MalariaGEN, we have not found ways to address these challenges. The complexity of community engagement exercises is widely recognized [24, 27, 32], and there may not be a one-size-fits-all solution. In our experience, however, these are significant challenges in the context of collaborative international genome research that require special attention when establishing and maintaining successful research networks. Scientific researchers cannot be expected to address these challenges alone, and constructive collaboration with others familiar with local community structures, processes and ethics is needed, preferably as an integral part of the research process. Meaningful legal protection of health privacy, while a popular concept, has proven difficult to establish as law.
Much of the pressure to access it stems from the usefulness of the data for insurers, employers and other business and regulatory actors. Public health also benefits from easy access to medical records. Monitoring would be improved in many cases by the ability to search for electronic medical records. At the very least, it traditionally depended on the ability of doctors to freely report cases to the health department. While protecting medical privacy has the potential to help reduce the perception of social risks associated with public health data collection, it is important to keep in mind that data protection laws that do not distinguish between public health and individual medical records will impose unnecessary and counterproductive burdens on public health work. The application of an informed consent requirement to information reported to or shared between ministries of health would be particularly harmful. Network infrastructure: When conducting research as part of an international collaboration, the network must identify the strengths and weaknesses of all partner sites and commit to sharing them with others. In particular, the network should try to support local analysis, for example by providing a data analyst at all locations. Opportunities for regular meetings to discuss specific challenges and a mentorship program to promote young scientists may also be considered. Students enrolled in professional education programs need to understand that ethical, legal, and social issues often overlap, resulting in a complex web of individual, professional, and societal obligations for physiotherapists.9 The social issue of equity in the workplace, for example, is also a professional ethical obligation for physiotherapists to their patients and is regulated by federal and anti-discrimination states. Similarly, courts are now reviewing health care codes of ethics as secondary sources of legal obligations, and licensing laws as well as state and regulatory laws flow from codes of professional ethics.
If the perception of risk through surveillance is a combination of fears and broader attitudes towards the use of genetic information, it can often be unnecessary to talk about the social risks of surveillance. The perception of high social risk associated with the information collected by everyone has the potential to influence acceptance of surveillance at one or both political levels (should surveillance be conducted?) and at the individual level (will individuals carrying genetic information avoid the data collection process?). In addition, individuals may be equally concerned about anticipated psychosocial and economic damage. It follows that promoting acceptance of surveillance depends on broader efforts to address the social risks of collecting genetic information and that more aspects of the problem must be considered than are necessarily contained in terms such as invasion of privacy and discrimination. The MalariaGEN network sought to address some of these challenges by co-developing a model for informed consent and guidelines for informed consent www.malariagen.net/home/ethics/consentpolicies.php. These were developed by and for MalariaGEN researchers and in consultation with selected members of the ethics committee. In addition, the MalariaGEN ethics team (JdV, SB and MP) discussed consent procedures, challenges and best practices with researchers and field staff from several research sites. Particular challenges related to consent were how to obtain consent in emergency situations and how to explain the reasons for taking samples from healthy children. A key strategy of genomic studies, such as the MalariaGEN study, is to compare genomic data between children with malaria (the cases) and healthy children (the controls). The collection of both types of samples raised questions about consent. Children who presented to the hospital were often seriously ill and needed immediate medical attention.
The timing of consent in this emergency was a real challenge in these cases. On the other hand, genomic study also requires taking blood samples from healthy children. Explaining the reason for collecting blood samples from healthy children was also a significant challenge for the MalariaGEN study. The complexity of addressing these issues was so great that further empirical research was conducted at two MalariaGEN research sites to investigate how best to obtain consent for genomic testing in low-income countries. Publications reflecting the results of these studies are being prepared. All states have newborn screening programs for certain congenital metabolic disorders for which early intervention with treatment provides a clear medical benefit to the child, such as phenylketonuria. Currently, the laws of at least two jurisdictions (District of Columbia and Maryland) clearly state that newborn screening is voluntary. 50 In at least two states (Montana and West Virginia), screening is mandatory and there is no legal provision for parental objections or refusals on religious grounds.51 In the other states, there are grounds for parental denial on religious or other grounds. Although the majority of states allow objections to screening on specific grounds, very few laws require parents or guardians of an infant to be properly informed that they can choose whether or not their child should be screened, or to be told they have the right to appeal.
52 Need AC, Goldstein DB: Next generation disparities in human genomics: concerns and remedies. Trends in genetics. 2009, 25 (11): 489-494. 10.1016/j.tig.2009.09.012. There are other challenges in obtaining valid consent for genome research. The information generated by genome research, for example, has the potential to shed light on people other than the research participant. There has been much discussion about the importance of data protection for individual research participants in genomic studies [41–43]. If personal identifiers are removed from genomic records, there may be a limited risk of participant identification. But even if this is the case, it is possible that unwanted information about populations, communities or families could be exposed.
At the population level, for example, GWA studies have the potential to show that stigmatizing disease is more likely to occur in one population than another [8]. In this sense, it raises the possibility that genomic data could be used in a way that would have adverse effects on affected populations, perhaps by generating research findings that could be used to stigmatize groups based on their genetic makeup [44, 45]. This type of issue may need to be taken seriously when designing consent processes for genomics. In the context of this diversity, it is inevitably difficult to find common ground where researchers can share their experiences and ideas.
